Colorectal Cancer

New Indication: Avelumab for MSI-High Metastatic Colorectal Cancer

2023-08-20

  • Study

    A Phase II, Randomized, Open-label, multicenter trial
    Progression under first-line treatment (except for immunotherapy) of dMMR/MSI metastatic colorectal cancer
    Avelumab (n=65) vs SOC (n=67)


  • Efficacy

    mOS: 25.8 vs. 23.4 mos, p=0.790
    mPFS: 4.1 vs. 6.2 mos, p=0.030
    12 mos PFS: 31.2% vs 19.4%
    18 mos PFS: 27.4% vs. 9.1%
    oRR: 29.5% vs 26.2%

  • Safety

    Grade3: Liver enzyme increased (7.9% vs.1.6%), diarrhea (4.8% vs.7.8%), neutropenia (0 vs.18.8%), hypertension (1% vs 10.9%).


    • JAMA Oncol, 3 AUG, 2023

    Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial

    http://doi.org/10.1001/jamaoncol.2023.2761

    Reviewed by Elvin Chalabiyev, MD on Aug 20, 2023